# Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS

> **NCT02360514** · PHASE3 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 226 (actual)

## Conditions studied

- Infection

## Interventions

- **DRUG:** Hantavax injection

## Key facts

- **NCT ID:** NCT02360514
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2015-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02360514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02360514, "Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02360514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*